I love the smell of manipulation in the morning.
Smells like - Victory!
While I understand your point, it would be a cruel irony if it helped get Drisapersen approved, then they found some reason to not approve Eteplirsen. I wonder if the FDA indicated to her that they plan to approve both?
Looking at the M&A targets in the biopharmaceutical space, several of the big ones have announced they are looking for small/niche companies to acquire. If GSK doesn't buy SRPT, someone else will. With that in mind, GSK could easily pick up SRPT and recoup much of its investment that went into the failed Dris.
GSK would be foolish to allow Pfizer to make the acquisition, so as a blocking takeover move, it is much smarter. Meaning, cheaper to acquire SRPT than to have to fight Pfizer/SRPT.
As for BMRN, I agree with you that after walking away from Dris they aren't likely to go back and pick up the whole company at a premium, especially when they can buy SRPT and simply knock out BMRN. So your logic is sound and I agree.
Think about it, GSK could buy BMRN and SRPT with their lunch money. So they could easily wait until the Adcom /FDA approval then buy the company outright in a stock swap and then THEY would own the DMD space in its entirety.
3-months later, I'm still waiting. What a train wreck of a Beta and of a company.
Shame, the product had such potential, they just can't execute.
I agree. He came across very professional, knowledgeable, and was a good corporate representative.
Agreed. The selloff was widespread after Hillary ran her mouth, harming the entire sector. Cramer used to be a big fan of ISIS then around $70 he stopped recommending it. I'm guessing it was his Hedge Fund buddies told him they were selling off some, which became a self fulfilling prophecy. Anyway, I fully agree that nothing has fundamentally changed with ISIS or the outstanding prospects going forward. Still the best pipeline in the industry!
Let's just hope Cramer doesn't weigh in, as he is the kiss of death no matter what he says.
You are too stupid to see beyond your own severe limitations.
Too dumb to learn.
How is it "obtuse" to look for other ways to earn money than simply to steal it from shareholders? Why are you so unable to see anything else?
Care to speculate on what it might be?
Clinical trials results from pipeline?
You keep arguing with yourself, about something I never said.
I believe the goal should be to cure. I never said Eteplirsen was a cure. Why do you keep arguing, trying to refute something I didn't say? You seem unable to see the bigger picture. That's OK many people have severe limitations.
It is sad though that you don't want anybody to find a cure. I believe the goal in the DMD community is to ultimately find a cure. Eteplirsen is a great step along the path, and while it doesn't cure, and never intended to - nor did I ever say it did - it does slow the degeneration, which is a step in the right direction. So I still maintain, the GOAL is to find a cure. It is so sad that you don't want a cure.
I never said Eteplirsen was a cure, never said we should change the goal of Eteplirsen- and I still can't figure out why you keep arguing something I never said. All I said was that the ultimate goal should be to cure patients. Why do you keep arguing with that.
I guess you don't want a cure.
Grey, that's all he's got, irrelevant arguments. Either way, SRPT is the preeminent leader in DMD treatment and the provider of choice for patients everywhere.
So far the screaming and wailing is coming from us longs stuck with a CFO that should have been fired long ago.